{"schema_version":"secwatch.filing_event.v1","accession":"0001867096-23-000006","form_type":"8-K","ticker":"XERS","cik":"0001867096","company_name":"Xeris Biopharma Holdings, Inc.","filed_at":"2023-01-20T23:59:59+00:00","discovered_at":"2026-05-14T18:03:47.267098+00:00","generated_at":"2026-06-20T12:41:37.167348+00:00","sec_items":["1.01"],"event_type":"other","sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"confidence":"medium","headline":"Xeris Biopharma amends credit deal to allow Letter of Financial Support to Australian unit","bullets":["Amendment No. 2 signed Jan 19, 2023; permits Xeris Pharma to issue a Letter of Financial Support to its Australian subsidiary.","Amendment modifies Credit Agreement dated March 8, 2022, with Hayfin Services as administrative agent.","No changes to principal, interest rate, or maturity under the existing credit facility."],"urls":{"canonical":"https://secwatch.observer/filing/0001867096-23-000006","json":"https://secwatch.observer/filing/0001867096-23-000006.json","markdown":"https://secwatch.observer/filing/0001867096-23-000006.md","text":"https://secwatch.observer/filing/0001867096-23-000006.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1867096/000186709623000006/0001867096-23-000006-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1867096/000186709623000006/xers-20230119.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-20T12:41:37.167348+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"5c40821d8a272c49d0aee1ef7d16901bb5425918","claim":"Xeris Biopharma Holdings, Inc. amended Amendment No. 2 to Credit Agreement and Guaranty with Hayfin Services LLP, as administrative agent, and the lenders parties thereto (effective 2023-01-19).","evidence_excerpt":"On January 19, 2023, Xeris Biopharma Holdings, Inc. (the “Company”) entered into Amendment No. 2 to Credit Agreement and Guaranty (“Amendment No. 2”) with Xeris Pharmaceuticals, Inc. (“Xeris Pharma”), the lenders parties thereto (the “Lenders”) and Hayfin Services LLP, as administrative agent for the Lenders (in such capacity, together with its successors and assigns, the “Agent”), to amend that certain Credit Agreement and Guaranty, dated as of March 8, 2022, as amended by Amendment No. 1 to Credit Agreement and Guaranty dated September 29, 2022 (the “Credit Agreement”), by and among the Company, Xeris Pharma, the subsidiary guarantors from time to time parties thereto, the Agent and the Lenders from time to time parties thereto.","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1867096/000186709623000006/0001867096-23-000006-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"amendment"},{"label":"Agreement","value":"credit facility"},{"label":"Counterparty","value":"Hayfin Services LLP, as administrative agent, and the lenders parties thereto"},{"label":"Effective","value":"2023-01-19"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}